AU2021381516A1 - Integrin inhibitor and uses thereof - Google Patents

Integrin inhibitor and uses thereof Download PDF

Info

Publication number
AU2021381516A1
AU2021381516A1 AU2021381516A AU2021381516A AU2021381516A1 AU 2021381516 A1 AU2021381516 A1 AU 2021381516A1 AU 2021381516 A AU2021381516 A AU 2021381516A AU 2021381516 A AU2021381516 A AU 2021381516A AU 2021381516 A1 AU2021381516 A1 AU 2021381516A1
Authority
AU
Australia
Prior art keywords
crystalline form
water content
degrees
theta
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021381516A
Other languages
English (en)
Other versions
AU2021381516A9 (en
Inventor
Jacob CHA
Katerina Leftheris
Gao Qi
Jian Wang
Dalian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of AU2021381516A1 publication Critical patent/AU2021381516A1/en
Publication of AU2021381516A9 publication Critical patent/AU2021381516A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2021381516A 2020-11-19 2021-11-19 Integrin inhibitor and uses thereof Abandoned AU2021381516A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116042P 2020-11-19 2020-11-19
US63/116,042 2020-11-19
PCT/US2021/072510 WO2022109598A1 (en) 2020-11-19 2021-11-19 Integrin inhibitor and uses thereof

Publications (2)

Publication Number Publication Date
AU2021381516A1 true AU2021381516A1 (en) 2023-06-22
AU2021381516A9 AU2021381516A9 (en) 2024-10-24

Family

ID=81709878

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021381516A Abandoned AU2021381516A1 (en) 2020-11-19 2021-11-19 Integrin inhibitor and uses thereof

Country Status (19)

Country Link
US (2) US12018025B2 (cg-RX-API-DMAC10.html)
EP (1) EP4247472A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023550428A (cg-RX-API-DMAC10.html)
KR (1) KR20230121761A (cg-RX-API-DMAC10.html)
CN (1) CN116710169A (cg-RX-API-DMAC10.html)
AU (1) AU2021381516A1 (cg-RX-API-DMAC10.html)
CA (1) CA3173755A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001418A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023006522A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230262A (cg-RX-API-DMAC10.html)
CU (1) CU20230026A7 (cg-RX-API-DMAC10.html)
DO (1) DOP2023000101A (cg-RX-API-DMAC10.html)
EC (1) ECSP23045278A (cg-RX-API-DMAC10.html)
IL (1) IL302651A (cg-RX-API-DMAC10.html)
JO (1) JOP20230102A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023005889A (cg-RX-API-DMAC10.html)
PE (1) PE20240114A1 (cg-RX-API-DMAC10.html)
TW (1) TW202235417A (cg-RX-API-DMAC10.html)
WO (1) WO2022109598A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
US20240122930A1 (en) * 2022-07-09 2024-04-18 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents
WO2024155965A2 (en) * 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy
US20250120975A1 (en) * 2023-09-25 2025-04-17 Pliant Therapeutics, Inc. Integrin inhibitors for treatment of primary sclerosing cholangitis
US20250197393A1 (en) 2023-12-14 2025-06-19 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
WO2025217571A1 (en) * 2024-04-12 2025-10-16 Pliant Therapeutics, Inc. Fixed dose combinations of integrin inhibitor with ppar agonists

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
ES2416354T3 (es) 2005-06-21 2013-07-31 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US8911952B2 (en) 2010-03-24 2014-12-16 Stc. Unm Method for integrin ligand discovery
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
IN2015DN00099A (cg-RX-API-DMAC10.html) 2012-07-18 2015-05-29 Univ Saint Louis
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
JP2018514568A (ja) 2015-04-30 2018-06-07 サイフルーア ライフ サイエンシズ インコーポレイテッド テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法
US10118929B2 (en) 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
WO2018183795A1 (en) 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds
CU24684B1 (es) * 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
JP7314135B2 (ja) * 2018-07-20 2023-07-25 株式会社半導体エネルギー研究所 撮像装置
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP3843728B1 (en) 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3903316A1 (en) * 2018-12-28 2021-11-03 LunaPBC Community data aggregation, completion, correction, and use
EP3923857B8 (en) * 2019-02-15 2024-04-17 Clean Bite, LLC Oral hygiene appliance
EP3952902A4 (en) * 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
CN115151566A (zh) 2019-11-15 2022-10-04 普利安特治疗公司 用于活化整合素的组合物和方法
KR20230049584A (ko) * 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료
TWI843503B (zh) * 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
TW202233224A (zh) * 2020-10-21 2022-09-01 美商寇峇有限公司 用組合療法治療纖維化之方法
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
US20230028658A1 (en) 2021-04-30 2023-01-26 Pliant Therapeutics, Inc. Expanded dosage regimens for integrin inhibitors
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
JP2024539645A (ja) 2021-10-14 2024-10-29 プライアント・セラピューティクス・インコーポレイテッド インテグリン阻害剤及び他の薬剤と組み合わせたその使用
WO2023225119A1 (en) 2022-05-18 2023-11-23 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors
US20240122930A1 (en) 2022-07-09 2024-04-18 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents
WO2024145245A2 (en) 2022-12-27 2024-07-04 Pliant Therapeutics, Inc. Alpha-v-beta-8 integrin inhibitors and uses thereof
WO2024155965A2 (en) 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy

Also Published As

Publication number Publication date
EP4247472A1 (en) 2023-09-27
MX2023005889A (es) 2023-06-06
US20220177468A1 (en) 2022-06-09
AU2021381516A9 (en) 2024-10-24
ECSP23045278A (es) 2023-07-31
DOP2023000101A (es) 2023-09-29
JOP20230102A1 (ar) 2023-05-08
CO2023006522A2 (es) 2023-06-09
CR20230262A (es) 2023-07-26
CN116710169A (zh) 2023-09-05
IL302651A (en) 2023-07-01
CA3173755A1 (en) 2022-05-27
US12018025B2 (en) 2024-06-25
JP2023550428A (ja) 2023-12-01
PE20240114A1 (es) 2024-01-22
TW202235417A (zh) 2022-09-16
EP4247472A4 (en) 2024-10-09
CU20230026A7 (es) 2024-01-10
KR20230121761A (ko) 2023-08-21
WO2022109598A1 (en) 2022-05-27
US12637462B2 (en) 2026-05-26
US20240391914A1 (en) 2024-11-28
CL2023001418A1 (es) 2023-10-30

Similar Documents

Publication Publication Date Title
US12018025B2 (en) Integrin inhibitor and uses thereof
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
ES3014022T3 (en) Angiotensin ii receptor antagonist metabolite and nep inhibitor composite, and preparation method thereof
ES2550771T3 (es) Sal de bismesilato etexilato de dabigatrán, formas en estado sólido y proceso para la preparación de las mismas
US9221815B2 (en) Solid state form of vemurafenib choline salt
CN106715439A (zh) 化合物
TW201335161A (zh) 二氫吡咯并[1,2-c]咪唑基皮質醛酮素合成酶或芳族酶抑制劑之新穎型式及鹽
US20240317764A1 (en) Salts and solid forms of a compound having apj receptor activity
AU2023305541A1 (en) Integrin inhibitors and uses thereof in combination with other agents
ES2463190B1 (es) Formas cristalinas de sartanes tales como telmisartán con betabloqueantes
TW201722950A (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
US20250197393A1 (en) Integrin inhibitor and uses thereof
KR102907394B1 (ko) Urat-1 억제제의 신규한 염 형태
CN104768927B (zh) (3s,3s’)‑4,4’‑二硫烷二基双(3‑氨基丁烷‑1‑磺酸)合l‑赖氨酸的新的结晶相
CN106431900A (zh) 新的多晶型物和盐
CN101981004B (zh) 晶体形式
CN105693699A (zh) 托吡司他的新晶型及其制备方法
EP3412661A1 (en) Cocrystals of vortioxetine hydrobromide and resorcinol
WO2023222122A1 (en) Solid forms of a compound for treating or preventing hyperuricemia or gout
WO2019015640A1 (zh) 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途
TW202521117A (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period